<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981212</url>
  </required_header>
  <id_info>
    <org_study_id>062IGA15-1D</org_study_id>
    <nct_id>NCT02981212</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy</brief_title>
  <acronym>AIGA</acronym>
  <official_title>Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the efficacy and safety of that test group
      was administered with Mycophenolate Mofetil in combination with corticosteroid in patients
      with advanced IgA nephropathy. The control group will be observed for up to 48 weeks without
      administration of Mycophenolate Mofetil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject who signed the written agreement to participate in the clinical trial evaluates
      the conformity and then 1: 1 randomly allocated.

      The study group were taken 48 weeks with MYREPT ® capsules in combination with
      corticosteroids and the control group were asked to preserve the conservative treatment
      regimen prior to the clinical trial registration Maintenance.

      The subject who started taking the study medicine will carry out the examination and
      procedure if it has to be carried out for the visit via outpatient clinic at 4 weeks, 12
      weeks, 24 weeks, 36 weeks, 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete / partial)</measure>
    <time_frame>up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate (complete / partial)</measure>
    <time_frame>at 12 weeks, at 24 weeks, at 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR(estimated glomerular filtration rate) by MDRD(modification of diet in renal disease)</measure>
    <time_frame>at 24 weeks, at 36 weeks, at 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of renal replacement therapy</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>renal replacement therapy; dialysis, new transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average time to occurrence of renal replacement therapy</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>renal replacement therapy; dialysis, new transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYREPT® capsule(CKDpharm, KOREA) and corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>maintain conservative treatment (ACE inhibitor or ARB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>MYREPT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization</description>
    <arm_group_label>Conservative treatment</arm_group_label>
    <other_name>conservative treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>combination with Mycophenolate Mofetil</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>prednisolone</other_name>
    <other_name>methyprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB</intervention_name>
    <description>maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization</description>
    <arm_group_label>Conservative treatment</arm_group_label>
    <other_name>conservative treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patient aged 19 to 65 years old

          2. Diagnosed with IgA nephropathy

          3. Confirmed with Proteinuria more than 1.0 g / day at least twice within 6 months from
             the time of screening

          4. If eGFR (by MDRD) is &lt;50 mL / min / 1.73 m^2, ≥ 15 mL / min / 1.73 m^2

          5. ACE inhibitor or ARB for at least 3 months

          6. Willing and able to provide written informed consent.

        Exclusion Criteria:

          1. If eGFR (by MDRD) is &lt;15 mL / min / 1.73 m^2

          2. Blood pressure is SBP&gt; 160 mmHg or DBP&gt; 100 mmHg

          3. Systemic infection or have been diagnosed with cancer within the last 5 years
             (excluding treatment squamous cell or basal cell carcinoma skin cancer)

          4. serious digestive disorder

          5. WBC &lt;3000 / mm^3

          6. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity
             reaction in the history of Investigational drugs

          7. Administration of other Investigational drugs within 28days before screening period

          8. Administration of Investigator drug or other immunosuppressants within 84days before
             screening period

          9. Women in pregnant or breast-feeding or don't using adequate contraception.

         10. Patient has conversation impairment because alcohol or drugs addiction history within
             6months or mental illness, etc.

         11. In investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BEOMSUK KIM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EUNJU JUNG</last_name>
    <phone>82-10-5414-7760</phone>
    <email>oakly74@nate.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JONGHYUK LEE</last_name>
    <phone>82-10-5599-1199</phone>
    <email>leejongh@ckdpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EUNU JUNG</last_name>
      <phone>82-10-5414-7760</phone>
      <email>oakly74@nate.com</email>
    </contact>
    <investigator>
      <last_name>CHANDUK KIM, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DONGWON LEE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SANGHO LEE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BUMSOON CHOI, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SANGYEOB HAN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SIK LEE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Beom Seok Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

